Bellicum Pharmaceuticals Inc., of Houston, said it closed its underwritten public offering of 575,000 shares of series 1 preferred stock and warrants to purchase up to 57.5 million shares of its common stock, at a combined price of $100 per share of series 1 preferred stock and accompanying warrant to purchase 100 shares of common stock. The aggregate offering size, before deducting the underwriting discounts and commissions and other offering expenses, was $57.5 million. In addition, Bellicum received a $12.1 million up-front option payment related to its agreement with certain institutional investors providing for a private placement exempt from the registration requirements of the Securities Act of 1933. The company has agreed to sell at two or more separate closings, each at the option of the investors and subject to certain conditions, shares of its series 2 preferred stock and warrants to purchase common stock, and shares of series 3 preferred stock and warrants to purchase common stock, for aggregate gross proceeds of up to $70 million.
Devonian Health Group Inc., of Quebec City, said it closed a non-brokered private placement of 1.26 million units at CA$0.25 each, for aggregate gross proceeds of CA$315,000 (US$236,880). Each unit is comprised of one subordinate voting share and one-half a subordinate voting share purchase warrant, where a whole purchase warrant entitles the holder to subscribe for one subordinate voting share at $0.50. The net proceeds will be used for working capital and general corporate purposes.
EW Healthcare Partners, of New York, said it raised over $745 million in EW Healthcare Partners Fund 2a L.P., its second dedicated growth equity fund. The fund will target fast-growing commercial-stage healthcare companies in the pharmaceutical, medical device, diagnostics, and technology-enabled services sectors in the U.S. and in Europe.
Finch Therapeutics Group Inc., of Somerville, Mass., said it completed a $53 million series C financing that will be used to advance a pipeline of microbial therapies, including CP-101, a full-spectrum microbiota (FSM) therapy delivered in an oral capsule that is designed to contain a diverse community of microbiota and restore a balanced microbiome. CP-101 is currently being evaluated for the prevention of recurrent C. difficile infections in the company's PRISM3 trial, a potentially pivotal clinical study. Positive results from the trial may be adequate to support FDA approval, based on recent communications with the agency, the company noted. The funding will also enable Finch to accelerate the development of its FSM therapy for autism spectrum disorder (ASD), a developmental condition characterized by behavioral symptoms and often accompanied by gastrointestinal (GI) symptoms. Studies suggest that GI and behavioral symptoms may be linked to a disrupted microbiome. Finch is supporting an actively enrolling, phase II, investigator-initiated clinical study evaluating the safety and efficacy of its FSM therapy in adults with ASD.
Helix Biopharma Corp., of Richmond Hill, Ontario, said it closed a private placement financing of 13.725 million units and the disposition of a 25% stake of its wholly-owned Polish subsidiary, Helix Immuno-Oncology SA, for aggregate gross proceeds of CA$7 million (US$5.26 million). The terms of the placement are for the purchase of units at $0.455 each. The unit is comprised of one common share and one common share purchase warrant entitling the holder to purchase one common share at CA $0.72. The company intends to use the net proceeds for working capital and research and development activities.
ONL Therapeutics Inc., of Ann Arbor, Mich., said it raised $3 million in a convertible note financing. The company is currently preparing its lead compound ONL-1204 for a phase I study in retinal detachment to be conducted in Australia later this year. The compound is a first-in-class small-molecule Fas inhibitor designed to protect key retinal cells, including photoreceptors, from cell death that occurs in a range of retinal diseases and conditions.